Eli Lilly signs oncology licensing and research deal with Stipple Bio

Eli Lilly signed a global oncology research and licensing collaboration with private biotech Stipple Bio that could provide Stipple with up to $5.9 billion. Lilly will make an upfront payment and equity investment, while Stipple may receive research, development and commercialization milestones plus tiered royalties. Lilly receives exclusive worldwide rights to develop and commercialize resulting therapies, and Stipple plans a Phase 1 trial of STP-100 in early 2027.

The agreement expands Lilly’s oncology pipeline and gives it worldwide rights to products emerging from Stipple’s platform. Lilly’s upfront payment and equity stake were not disclosed, while much of the potential consideration depends on future development and commercialization milestones.

  • 1The collaboration could provide Stipple Bio with up to $5.9 billion, including milestone payments and royalties.
  • 2Lilly receives exclusive worldwide rights to develop and commercialize therapies resulting from the partnership.
  • 3The agreement includes an upfront payment and an equity investment from Lilly, but the amounts were not disclosed.
  • 4Stipple plans to begin a Phase 1 trial for STP-100 in early 2027 for solid tumors, including pancreatic cancer.
  • 5Stipple’s Pointillist Platform is intended to identify tumor-specific cell-surface epitope binders.
  • The size of Lilly’s upfront payment and equity investment was not disclosed.
  • The ultimate value of the agreement depends on research, development and commercialization milestones and future product sales.

Sources